UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Organon & Co. (NYSE:OGN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 21.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,016,351 shares of the company's stock after purchasing an additional 179,962 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.39% of Organon & Co. worth $15,164,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in OGN. Barclays PLC grew its stake in shares of Organon & Co. by 238.0% during the third quarter. Barclays PLC now owns 119,483 shares of the company's stock worth $2,285,000 after buying an additional 84,136 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Organon & Co. by 107.6% during the 4th quarter. Blue Trust Inc. now owns 7,599 shares of the company's stock valued at $113,000 after acquiring an additional 3,938 shares in the last quarter. KBC Group NV grew its position in Organon & Co. by 66.6% during the 4th quarter. KBC Group NV now owns 12,899 shares of the company's stock worth $192,000 after acquiring an additional 5,155 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in Organon & Co. during the 4th quarter worth $2,263,000. Finally, Allen Capital Group LLC acquired a new position in Organon & Co. in the 4th quarter worth about $150,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 2.0%

OGN traded up $0.19 during trading on Tuesday, reaching $9.44. 4,171,213 shares of the stock traded hands, compared to its average volume of 3,332,474. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The stock's 50-day moving average is $10.71 and its 200 day moving average is $13.72. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $23.10. The stock has a market capitalization of $2.45 billion, a PE ratio of 2.83, a P/E/G ratio of 0.90 and a beta of 0.75.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.13. The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company's quarterly revenue was down 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.22 earnings per share. Equities analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Monday, May 12th will be paid a dividend of $0.02 per share. The ex-dividend date is Monday, May 12th. This represents a $0.08 dividend on an annualized basis and a yield of 0.85%. Organon & Co.'s dividend payout ratio (DPR) is presently 2.78%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on OGN shares. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Piper Sandler cut their target price on shares of Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research report on Thursday, May 15th. Morgan Stanley decreased their price target on shares of Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. Finally, Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $18.00.

Insiders Place Their Bets

In other news, CEO Kevin Ali purchased 34,000 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were acquired at an average cost of $8.80 per share, for a total transaction of $299,200.00. Following the completion of the acquisition, the chief executive officer now owns 282,731 shares in the company, valued at $2,488,032.80. This trade represents a 13.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel Karp acquired 3,500 shares of Organon & Co. stock in a transaction on Tuesday, May 6th. The stock was purchased at an average cost of $8.24 per share, with a total value of $28,840.00. Following the completion of the transaction, the vice president now directly owns 46,669 shares in the company, valued at $384,552.56. This represents a 8.11% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 102,345 shares of company stock worth $902,430. Insiders own 1.96% of the company's stock.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.